BioSpace News Archive

BioCopy AG announces a collaboration with Immatics N.V. “Immatics” in the field of characterization of T cell receptors.

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announces that senior members of the executive team will be participating at the following events.

Royal Philips announced that the first patient has been enrolled in the WE-TRUST study at Vall d’Hebron University Hospital, Barcelona, Spain, marking the official start of this major multicenter randomized controlled trial to assess if the Direct to Angio Suite workflow can improve outcomes for early time-window stroke patients.

Royal Philips, a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company.

Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has concluded a commercial partnership with Teva Pharmaceutical Industries Ltd. for their biosimilar candidate of the ophthalmological drug Ranibizumab in Europe, Canada, Israel and New Zealand.

Cartilage of the knee joint, when severely damaged by age related wear and tear or injury or osteoarthritis, which is removed and usually discarded, during joint replacement surgery, now could be rejuvenated, becoming a potential source of cells for cell therapy through a disruptive technology that reverses aging, confirmed by Senescence associated ß-Galactosidase, p16 and p21, markers, published in Scientific Reports, a Nature journal.

RepliCel Life Sciences Inc. is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare for approval to manufacture the Company’s RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an independent consensus study of 32 leading wound care clinicians in Diagnostics1.

ViewRay, Inc. announced that the Miami Cancer Institute, part of Baptist Health South Florida, has enrolled the first patients in its “Stereotactic MRI-guided Adaptive Radiation Therapy in One Fraction for Inoperable Primary or Metastatic Carcinoma” clinical study – referred to as the SMART ONE trial.

Mallinckrodt plc, a global biopharmaceutical company, announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of StrataGraft®, which is approved for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated.